Prodrugs in nasal drug delivery

Bibliography

• BUNDGAARD H: Design of prodrugs: bioreversible derivatives for various functional groups and chemical entities. In: Design of Prodrugs. H Bundgaard (Ed.), Elsevier, NY, USA (1985):1–92.
   Google Scholar
• SINKULA AA, YALKOWSKY SH: Rationale for the design of biologically reversible drug derivatives: prodrugs. Pharm. ScL (1975) 64:181–210.
   PubMed Web of Science ®Google Scholar
• STELLA V: Prodrugs as Novel Drug Delivoy Systems. Higuchi T, Stella V (Eds.), American Chemical Society, Washington, DC, USA (1975):1–115.
   Google Scholar
• WATANABE K, WATANABE I, SAITO Y, MIZUHIRA V: Characteristics of capillary permeability in nasal mucosa. Ann. OM]. (1980) 89:377–382.
   Google Scholar
• DAHLIN M, BJORK E: Nasal absorption of (S)-UI-1-301 and its transport into the cerebrospinal fluid of rats. Int. J. Pharm. (2000) 195:197–205.
   PubMed Web of Science ®Google Scholar
• CORNAZ AL, BURI P: Nasal mucosa as an absorptionbarrier. Eur. J. Pharm. Biopharm. (1994) 40:261–270.
   Web of Science ®Google Scholar
• HIRAI S, YASHIKI T, MATSUZAWA T, MIMA H: Absorp-tion of drugs from the nasal mucosa of rat. Int. J. Pharm. (1981) 7:317–325.
   Web of Science ®Google Scholar
• MCMARTIN C, HUTCHINSON LE, HYDE R, PETERS GE:Analysis of structural requirements for the absorption of drugs and macromolecules from the nasal cavity. J. Pharm. Sci. (1987) 76:535–540.
   PubMed Web of Science ®Google Scholar
• HAYASHI M, HIRASAWA T, MURAOKA T, SHIGA M, AWAZU S: Comparison of water influx and sieving coefficient in rat jejunal, rectal and nasal absorptions of antipyrine. Chem. Pharm. Bull. (1985) 33:2149–2152.
   PubMed Web of Science ®Google Scholar
• FISHER AN, ILLUM L, DAVIS SS, SCHACHT EH: Di-iodo-htyrosine-labelled dextrans as molecular size markers of nasal absorption in the rat. J. Pharm. Pharmacol (1992) 44:550–554.
   PubMed Web of Science ®Google Scholar
• LEE VH, YAMAMOTO A, KOMPELLA UB: Mucosal penetration enhancers for facilitation of peptide and protein drug absorption. Grit. Rev. Ther. Drug Carr. Sys. (1991) 8:91–192.
   PubMed Web of Science ®Google Scholar
• WILSON CG, WASHINGTON N: Overview of epithelialbarriers and drug transport. In: Physiological Pharma-ceutics: Biological Barriers to Drug Absorption. Rubinstein MH (Ed.), Ellis Horwood Ltd., New York, USA (1989):11–20.
   Google Scholar
• CREMASCHI D, ROSSETTI C, DRAGHETTI MT, MANZONI C, ALIVERTI V: Active transport of polypeptides in rabbit nasal mucosa: possible role in the sampling of potential antigens. Eur. J. Phys. (1991) 419:425–432.
   Web of Science ®Google Scholar
• HOSOYA K, KUBO H, NATSUME H, SUGIBAYASHI K, MORIMOTO, YASUNORI Y: The structural barrier of absorptive mucosae: site difference of the permeability of fluorescein isothiocyanate-labeled dextran in rabbits. Biopharm. Drug Dispos. (1993) 14: 685–695.
   PubMed Web of Science ®Google Scholar
• HERSEY SJ, JACKSON RT: Effect of bile salts on nasalpermeability in vitro. J. Pharm. Sci. (1987) 76:876–879.
   PubMed Web of Science ®Google Scholar
• CORBO DC, LIU JC, CHIEN YVV: Characterization of the barrier properties of mucosal membranes. J. Pharm. Sci. (1990) 79:202–206.
   PubMed Web of Science ®Google Scholar
• DUERLOO MJ, HERMENS WA, ROMEYN SG, VERHOEF JC, MERKUS FW: Absorption enhancement of intranasally administered insulin by sodium taurodihydrofusidate (STDHF) in rabbits and rats. Pharm. Res. (1989) 6:853–856.
   PubMed Web of Science ®Google Scholar
• FISHER AN, BROWN K, DAVIS SS, PARR GD, SMITH DA: The nasal absorption of sodium cromoglycate in the albino rat. J. Pharm. Pharmacol (1985) 37:38–41.
   PubMed Web of Science ®Google Scholar
• PUCHELLE E: Mucus and mucociliary clearance. In: Buccal and Nasal Administration as an Alternative to Parenteral Administration. European symposium APGI, Editions de Sante Paris (1990:29–39.
   Google Scholar
• AINGE G, BOWLES JA, McCORMICK SG, RICHARDS DH, SCALES MD: lack of deleterious effects of corticos-teroid sprays containing benzalkonium chloride on nasal ciliated epithelium. In vivo results in laboratory animals. Drug. Invest. (1994) 8:127–133.
   Google Scholar
• LEE VHL, AYAMAMOTO M: Penetration and enzymaticbarriers of peptides and protein absorption. Adv. Drug Del. Rev. (1990) 4:171–207.
   Google Scholar
• DAHL AR: The effect of cytochrome p450 dependent metabolism and other enzyme activities on olfaction. In: Molecular Neurobiology of the Olfactory System. Margolez FL, Getchell TV (Eds.), Plenum Press, New York, USA (1988):51–70.
   Google Scholar
• BOGDANFFY MS: Biotransformation enzymes in the rodent nasal mucosa; The value of a histochemical approach. Environ. Health Perspect. (1990) 85:177–186.
   PubMed Web of Science ®Google Scholar
• BOGDANFFY MS, RANDALL HW, MORGAN KT: Histochemical localization of aldehyde dehydroge-nase in the respiratory tract of the Fisher-344 rat. Toxicol. Appl. Pharmacol. (1985) 82:560–563.
   Web of Science ®Google Scholar
• BOGDANFFY MS, RANDALL HW, MORGAN KT: Biochemical quantitation and histochemical localiza-tion of carboxylesterase in the nasal passages of the Fisher-344 rat and B6C3F1 mouse. Toxicol. Appl. Pharmacol. (1987) 88:183–194.
   PubMed Web of Science ®Google Scholar
• BOGDANFFY MS, KEE CR, HINCHMAN CA, TRELA BA: Metabolism of dibasic esters by rat nasal mucosal carboxylesterase. Drug Metab. Dipos. (1991) 19:124–129.
   PubMed Web of Science ®Google Scholar
• GERVASI PG, LONGO V, URSINO F, PANATTONI G: Drug metabolizing enzymes on the respiratory mucosa of humans. In: Cytochrome P 450: Biochemistry and Biophysics. Schuster I (Ed.), Taylor and Francis, NY, USA (1989)97.
   Google Scholar
• BOND JA, HERKIMA JR, RUSSEL VI: Regional distribution of xenobiotic metabolizing enzymes in respiratory airways of dogs. Drug Metab. Dispos. (1988) 16:116–124.
   PubMed Web of Science ®Google Scholar
• JACOBY WB, KETTERER B, MANNERVIK B: Glutathionetransferases: nomenclature. Biochem. Pharmacol. (1984) 33:2539–2540.
   PubMed Web of Science ®Google Scholar
• ACETO A, ILIO CD, ANGELUCCI S, LONGO V, GERVASI PG, FEDERICI G: Glutathione in human nasal mucosa. Arch. Toxicol. (1989) 63:427–431.
   PubMed Web of Science ®Google Scholar
• SARKAR MA: Drug metabolism in the nasal mucosa. Pharm. Res. (1992) 9:1–9.
   PubMed Web of Science ®Google Scholar
• ZHOU XH, PO AL: Comparison of enzyme activities of tissues lining portals of absorption of drugs: species differences. Int. J. Pharm. (1991) 70:271–283.
   Google Scholar
• HUANG CH, KIMURA R, BAWARSHI-NASSAR R, HUSSAINA: Mechanism of nasal absorption of drugs I. Physico-chemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J. Pharm. Sci. (1985) 74:608–611.
   Google Scholar
• HUANG CH, KIMURA R, BAWARSHI-NASSAR R, HUSSAINA: Mechanism of nasal absorption of drugs II. Absorp-tion of L tyrosine and the effect of structural modifica-tion on its absorption. I Pharm. Sci. (1985) 74:1298–1301.
   Google Scholar
• MURANISHI S: Absorption enhancers. Grit. Rev. Ther. Drug Carrier Sys. (1990) 7:1–33.
   PubMed Web of Science ®Google Scholar
• HUSSAIN A, BAWARSHI-NASSAR R, HUANG CH: Physico-chemical considerations in intranasal drug admini-stration. In: Transnasal Systemic Medications. Chien YVV (Ed), Elsevier, Amsterdam, The Netherlands (1985):121–137.
   Google Scholar
• DUCHENE D, PONCHEL G: Nasal administration: a tour for tomorrow's systemic administration of drugs. Drug. Dev. Ind. Pharm. (1993) 19:101–122,
   Web of Science ®Google Scholar
• OHWAKI T, ANDO H, WATANABE S, MIYAKE Y: Effects of dose, pH and osmolarity on nasal absorption of secretin in rats. J. Pharm. Sci. (1985) 74:550–552.
   PubMed Web of Science ®Google Scholar
• OHWAKI T, ANDO H, KAKIMOTO F eta].: Effects of dose, pH and osmolarity on nasal absorption of secretin in rats II: histological aspects of the nasal mucosa in relation to the absorption variation due to the effects of pH and osmolarity.j Pharm. Sci. (1987) 76:695–698.
   Google Scholar
• OHWAKI T, ISHII M, AOKI S et al.: Effect of dose, pH and osmolarity on nasal absorption of secretin in rats. M. In vitromembrane permeation test and determination of apparent partition coefficient of secretin. Chem. Pharm. Bull. (1989) 37:3359–3362.
   Google Scholar
• HIRAI S, YASHIKI P, MIMA H: Mechanisms for the enhancement of nasal absorption of insulin by surfac-tants. Int. J. Pharm. (1981) 9:173–184.
   Web of Science ®Google Scholar
• KANEO Y: Absorption from the nasal mucus membrane: I. Nasal absorption of hydralazine in rats. Acta. Pharm. Suec. (1983) 20:379–388.
   PubMedGoogle Scholar
• CORBO DC, LIU JC, CHIEN YW: Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharm. Res. (1989) 6:848–852.
   PubMed Web of Science ®Google Scholar
• GONDA I. GIPPS E: Model of disposition of drugs administered into the human nasal cavity. Pharm. Res. (1990) 7:69–75.
   PubMed Web of Science ®Google Scholar
• ILLUM L: The nasal delivery of peptides and proteins. Trends Biotech. (1991) 9:284–289.
   PubMed Web of Science ®Google Scholar
• SAKANE T, AKIZUKI M, TAKI Y, YAMASHITA S, SEZAKI H, NADAI T: Direct drug transport from the rat nasal cavity to the cerebrospinal fluid: the relation to the molecular weight of drugs. J. Pharm. Pharmacol. (1995) 47:379–381.
   PubMed Web of Science ®Google Scholar
• BEHL CR, PIMPLASKAR HK, SILENO AP, DEMIRELES J, ROMEO VD: Effects of physicochemical properties and other factors on systemic nasal drug delivery. Adv. Drug Del. Rev. (1998) 29:89–116.
   PubMed Web of Science ®Google Scholar
• YAMASHITA S, TANAKA Y, ENDOH Y et al.: Analysis of drug permeation across Caco-2 monolayer: implica-tion for predicting in vivo drug absorption. Pharm. Res. (1997) 14:486–491.
   PubMed Web of Science ®Google Scholar
• LEE CH, KIM HJ: A study on the absorption mechanism of drugs through biomembranes. Arch. Pharmacol Res. (1994) 17:182–189.
   Google Scholar
• KIMURA T, SUDO K, KANZAKI Y et al.: Drug absorption from large intestine: physicochemical factors governing drug absorption. Biol. Pharm. Bull. (1994) 17:327–333.
   PubMed Web of Science ®Google Scholar
• GIBSON, RICHARD E, OLANOFF LS: Physicochemicaldeterminants of nasal drug absorption. j Contol. Rel. (1987) 6:361–366.
   Google Scholar
• DUCHATEAU JS, ZUIDEMA J, ALBERS WM, MERKUS FW:Nasal absorption of alprenolol and metaprolol. Int. J Pharm. (1986) 34:131–136.
   Web of Science ®Google Scholar
• RUBINSTEIN A: Intranasal administration ofgentamicin in human subjects. Antimicrob. Agents Chemother. (1983) 23:778–779.
   PubMed Web of Science ®Google Scholar
• CORBO DC, HUANG YC, CHIEN YVV: Nasal delivery ofprogestational steroids in ovariectomized rabbits II: Effect of penetrant hydrophilicity. Int. J Pharm. (1989) 50: 253–260.
   Web of Science ®Google Scholar
• HUSSAIN A: Intranasal drug delivery. Adv. Drug Del. Rev.(1998) 29:39–49.
   PubMed Web of Science ®Google Scholar
• HUSSAIN A; HAMADI S; KAGASHIMA M; ISEKI K, DITTERT L: Does increasing the lipophilicity of peptides enhance their nasal absorption? J Pharm. Sci. (1991) 80:1180–1181.
   Google Scholar
• DONOVAN MD, FLYNN GL, AMIDON GL: Absorption ofpolyethylene glycols 600 through 2000: the molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. (1990) 7:863–868.
   PubMed Web of Science ®Google Scholar
• DONOVAN MD. FLYNN GL. AMIDON GL: The molecular weight dependence of nasal absorption: the effect of absorption enhancers. Pharm. Res. (1990) 7:808–815.
   PubMed Web of Science ®Google Scholar
• DONOVAN MD; HUANG Y: large molecule and particu-late uptake in the nasal cavity: the effect of size on nasal absorption. Adv. Drug Del. Rev. (1998) 29:147–155.
   PubMed Web of Science ®Google Scholar
• FISHER AN, BROWN K; DAVIS SS, PARR GD, SMITH DA: The effect of molecular size on the nasal absorption of water-soluble compounds in the albino rat. J Pharm. Pharmacol. (1987) 39:357–362.
   PubMed Web of Science ®Google Scholar
• NARURKAR, MM, MITRA AK: Synthesis, physico-chemical properties and cytotoxicity of a series of St-ester prodrugs of 5 -iodo-2t-deoxyuridine. Pharm. Res. (1988) 5:734–737.
   PubMed Web of Science ®Google Scholar
• GHOSH MK, MITRA AK: Effects of St-ester modification on the physicochemical properties and plasma protein binding of 5 -iodo-2t-deoxyuridine. Pharm. Res. (1991) 8:71–75.
   Web of Science ®Google Scholar
• GHOSH MK, MITRA AK: Enhanced delivery of 5 -iodo-2'-deoxyuridine to the brain parenchyma. Pharm. Res. (1992) 9:1173–1176.
   PubMed Web of Science ®Google Scholar
• SAYANI AP, CHIEN YVV: Systemic delivery of peptides and proteins across absorptive mucosae. Grit. Rev. Ther. Drug Car. Systems (1996) 13:85–184.
   PubMed Web of Science ®Google Scholar
• MOESS J, BUNDGAARD H: Pr odrugs of peptides: Bioreversible derivatization of thyrotropin-releasing hormone (TRH) by N-phthalidylation of its imidazole moiety. Int. J. Pharm. (1991) 74:67–75.
   Web of Science ®Google Scholar
• BARLOW D, TAKASHI S: The design of peptideanalogues for improved absorption. J Cont. Rel. (1994) 29:283–291.
   Web of Science ®Google Scholar
• KRISHNAMOORTHY R, MITRA AK: Prodrugs for nasaldelivery. Adv. Drug Del. Rev. (1998) 29:135–146.
   PubMed Web of Science ®Google Scholar
• RASMUSSEN GJ, BUNDGAARD H: Pr odrugs of peptides.15, 4- imidazolidinone prodrug derivatives of enkephalins to prevent aminopeptidase catalyzed metabolism in plasma and absorptive mucosae. Int. J Pharm. (1991) 76:113–122.
   Google Scholar
• PAULETTI GM, GANGAWAR S, OKUMU FW, SIAHAAN TJ,STELLA VJ, BORCHARDT RT: Esterase sensitive cyclic prodrugs of peptides: Evaluation of an acyloxyalkoxy promoiety in a model hexapeptide. Pharm. Res. (1996) 13:1615–1623.
   PubMed Web of Science ®Google Scholar
• BUNDGAARD H: The utility of prodrug approach toimprove peptide absorption. J. Cont. Ref (1992) 21:63–72.
   Web of Science ®Google Scholar
• HUSSAIN MA, AUNGST BJ, KAPIL R, MOUSA SA: Intranasal absorption of the platelet glycoprotein I1b/Illa receptor antagonist, DMP 755 and the effect of anesthesia on nasal bioavailability. j Pharm. Sci. (1997) 86:1358–1360.
   PubMed Web of Science ®Google Scholar
• SHAO Z, MITRA AK: Nasal membrane and intracellularprotein and enzyme release by bile salts and bile salt-fatty acid mixed micelles: Correlation with facili-tated drug transport. Pharm. Res. (1992) 9:1184–1189.
   PubMed Web of Science ®Google Scholar
• PARK JB, SHAO Z, MITRA AK: Acyclovir permeationenhancement across intestinal and nasal mucosa by bile salt- acylcarnitine mixed micelles. Pharm. Res. (1992) 9:1262–1267.
   PubMed Web of Science ®Google Scholar
• SHAO Z: PhD thesis. Purdue University, West Lafayette, IN,USA (1994).
   Google Scholar
• SHAO Z, PARK JB, KRISHNAMOORTHY R, MITRA AK: Physicochemical properties, plasma enzymatic hydrolysis and nasal absorption of acyclovir and its 2'-ester prodrugs. Pharm. Res. (1994) 11:237–242.
   PubMed Web of Science ®Google Scholar
• SHAO Z, MITRA AK: Bile salt-fatty acid mixed micellesas nasal absorption promoters III. Effects of nasal transport and enzymatic degradation of acyclovir prodrugs. Pharm. Res. (1994) 11:3243–3250.
   Google Scholar
• SHAO Z, HOFFMAN AJ, MITRA AK: Biodegradationcharacteristics of acyclovir 2t-esters by respiratory carboxylesterases: Implications in prodrug design for intranasal and pulmonary drug delivery. Int. J. Pharm. (1994) 112:181–190.
   Web of Science ®Google Scholar
• SAKANE T, AKIZUKI M; YAMASHITA S, NADAI T, HASHIDA M, SEZAKI H: The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. Chem. Pharm. Bull. (1991) 39:2456–2458.
   PubMed Web of Science ®Google Scholar
• SAKANE T, AKIZUKI M; YOSHIDA M et al.: Transport ofcephalexin to the cerebrospinal fluid directly from the nasal cavity. J. Pharm. Pharmacol. (1991) 43:449–451.
   Google Scholar
• SHINGAKI T, SAKANE T, YAMASHITA S, SEZAKI H, TOKUNAGA Y, SHIBATA S: Transnasal delivery of anticancer drugs to the brain tumour: a new strategy for brain tumour chemotherapy. Drug Delivery Sys. (1999) 14:365–371.
   Google Scholar
• SAKANE T, YAMASHITA S, NADAI T, SEZAKI H: Direct drug transport from the nasal cavity to the cerebro-spinal fluid. A new strategy for drug delivery to the brain. STP Pharma Sci. (1997) 7:98–106.
   Google Scholar
• JOHNSON RT, MIMS CA: Pathogenesis of the viral infection of the nervous system. N Engl. J. Med. (1968) 278:23–30.
   PubMed Web of Science ®Google Scholar
• CZERNIAWSKA A: Experimental investigations on the penetration of 198Au from into cerebrospinal fluid. 70:58–61.
   Google Scholar
• KUMAR TC, ANAND D, SANKARANARAYANAN A, PURI, V,SUNDARAM KR: Pharmacokinetics of progesterone after its administration to ovariectomized rhesus monkeys by injection, infusion, or nasal spraying. Proc. Natl. Acad. Sci. USA (1982) 79:4185–4189.
   PubMed Web of Science ®Google Scholar
• CHOU KJ, DONOVAN MD: Distribution of antihista-mines into the CSF following intranasal delivery. Biopharm. Drug Dispos. (1997) 18:335–346.
   PubMed Web of Science ®Google Scholar
• LIU J, FREY WH, RAHMAN YE: New approach to Alzheimer therapy: Delivery of nerve growth factor (NGF) to the brain through the olfactory pathway and assessment of NGFintegrity. Pharm. Res. (1994)11 :S208.
   Google Scholar
• TAKASAWA K; TERASAKI T; SUZUKI H, 00IE T, SUGIYAMA Y: Distributed model analysis of 3t-azido-3t-deoxythymidine and 2t-,3t-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J Pharmacol. Exp. Ther. (1997) 282:1509–1517.
   PubMed Web of Science ®Google Scholar
• The Physiology and Pathophysiology of the CerebrospinalFluid. Davson H, Welch K, Segal MB (Eds.), Churchill Livingstone, London, UK (1987).
   Google Scholar
• YAJIMA T, JUNI K, SANEYOSHI M, HASEGAWA T, KAWAGUCHI T: Direct transport of 2'3'-didehydro-3t-deoxythymidine (D4T) and its ester derivatives to the cerebrospinal fluid via the nasal mucous membrane in rats. Biol. Pharm. Bull. (1998) 21:272–277.
   PubMed Web of Science ®Google Scholar
• KAO HD, TRABOULSI A, ITOH S, DITTERT L, HUSSAIN A: Enhancement of the systemic and CNS specific delivery of hdopa by the nasal administration of its water soluble prodrugs. Pharm. Res. (2000) 17:978–984.
   PubMed Web of Science ®Google Scholar
• BEAUCHAMP LM, ORR GF, DE MIRANDA P, BURNETTE T,KRENITSKY TA: Amino acid ester prodrugs of acyclovir. Antiviral Chem. Chemother. (1992) 3:157–164.
   Web of Science ®Google Scholar
• DEVRUEH RL, SMITH PL, LEE CP: Transport of hyaline-acyclovir via the oligopeptide transporter in the nasal mucosa membrane Acta Otolaryngol. (1970) human intestinal cell line, Caco-2. J. Pharmacol. Exp Ther. (1998) 286:1166–1170.
   Google Scholar
• HUM, BORCHARDT RT: Mechanism of ha-methyldopa transport through a monolayer of polarized human intestinal epithelial cell (Caco-2). Pharm. Res. (1990) 7:1313–1319.
   PubMed Web of Science ®Google Scholar
• HU M, SUBRAMANIAN P, MOSBERG HI, AMIDON GL: Use of the peptide carrier system to improve the intestinal absorption of L-a-methyldopa: carrier kinetics, intestinal permeabilities and in vitro hydrolysis of dipeptidyl derivatives of ha-methyldop a. Pharm. Res. (1989) 6:66–70.
   PubMed Web of Science ®Google Scholar
• MIZUMA T, OHTA K, HAYASHI M, AWAZU S: Intestinal active absorption of sugar-conjugated compounds by glucose transport system: implication of improve-ment of poorly absorbable drugs. Biochem. Pharmacol. (1992) 43:2037–2039.
   PubMed Web of Science ®Google Scholar
• MIZUMA T, OHTA K, HAYASHI M, AWAZU S: Compara-tive study of active absorption by the intestine and disposition of anomers of sugar-conjugated compounds. Biochem. Pharmacol (1993) 45:1520–1523.
   PubMed Web of Science ®Google Scholar
• HOKARI M, WU HQ, SCHVVARCZ R, SMITH QR: Facilitated brain uptake of 4-chlorokynurenine and conversion to 7-chlorokynurenic acid. Neuroreport (1996) 8:15–18.
   PubMed Web of Science ®Google Scholar
• WALKER I, NICHOLLS D, IRWIN WJ, FREEMAN S: Drug delivery via active transport at the blood-brain barrier: affinity of a prodrug of phosphonoformate for the large amino acid transporter. Int. j Pharm. (1994) 104:157–167.
   Web of Science ®Google Scholar
• GALIETTA LJV, MUSANTE L, ROMIO L et al: An electro-genic amino acid transporter in the apical membrane of cultured human bronchial epithelial cells. Am. J Physiol. (1998) 275:L917–L923.
   PubMed Web of Science ®Google Scholar
• TENGAMNUAY P, MITRA AK: Transport of tyrosine and phenylalanine across the rat nasal mucosa. Life Sci. (1988) 43:585–593.
   PubMed Web of Science ®Google Scholar
• CREMASCHI D, ROSSETTI C, DRAGHETTI MT, MANZONI C, ALIVERTI V: Active transport of polypeptides in rabbit nasal mucosa: possible role in the sampling of potential antigens. Pflug Arch (1991) 410:425–432.
   Google Scholar
• TENGAMNUAY P, MITRA AK: Systemic absorption of h and D- phenylalanine across the rat nasal mucosa. Life Sci. (1991) 48:1477–1481.
   PubMed Web of Science ®Google Scholar
• YANG C, MITRA AK: Nasal absorption of tyrosine linked model compounds. J. Pharm. Sci. (In Press).
   Google Scholar
• YANG C, MITRA AK: Chemical stability, enzymatic hydrolysis and nasal uptake of amino acid ester prodrugs of acyclovir. J. Pharm. Sci. (In Press).
   Google Scholar
• YANG C, MITRA AK: Cellular uptake of L-tyrosine and its competitive inhibition by L-aspartate 13 ester of acyclovir in human airway epithelial cell line. (Manuscript in Preparation).
   Google Scholar